NCT00079677View on ClinicalTrials.gov

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

October 31, 2004

Conditions
Obstructive Sleep ApneaSleep Hypopnea
Interventions
DRUG

Armodafinil 150 mg/day

Armodafinil 150 mg once daily in the morning

DRUG

Placebo

Matching placebo tablets once daily

Sponsors

Lead Sponsor

Cephalon
All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00079677 - Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome | Biotech Hunter | Biotech Hunter